November 18, 2024 11:03 AM EST

As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

Ayisha Sharma

News Reporter

Alnylam’s experimental RNAi treatment for a rare form of cardiomyopathy has shown signs of efficacy in an early-stage trial of healthy volunteers, but analysts said …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

Ayisha Sharma

News Reporter

Sign up to read this article for free.

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials

As car­diomy­opa­thy mar­ket ex­pands, Al­ny­lam of­fers look at Phase 1 da­ta in healthy vol­un­teers

Ayisha Sharma

News Reporter

Sign up to read this article for free.

more like this

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

CagriSema’s weight loss data disappointed. What does Novo do next?

Three drugmakers sue US over 340B discounts to STD clinics they allege don’t qualify

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Bristol Myers' TYK2 inhibitor succeeds in pair of Phase 3 psoriatic arthritis trials